Previous 10 | Next 10 |
Shares of Cellectics (NASDAQ: CLLS) , a clinical-stage biopharmaceutical company that specializes in oncology, rose 22.7% this week, according to data from S&P Global Market Intelligence . The stock closed last Friday at $3.17, then opened Monday at $3.19. It reached its hig...
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today will present its first research...
Cellectis S.A. (CLLS) Q1 2022 Earnings Conference Call May 13, 2022 8:00 A.M. ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Carrie Brownstein - Chief Medical Officer Bing Wang - Chief Financial Officer Conference Call Participants Gena ...
Cellectis press release (NASDAQ:CLLS): Q1 Non-GAAP EPS of -$0.64 beats by $0.02. Revenue of $3.83M (-86.3% Y/Y) misses by $14.68M. "Based on our current operating plan, our cash position of $142M at the end of the first quarter 2022, is expected to fund our operations into early 2024." ...
◦ UCART20x22 preclinical data presented at AACR demonstrated PoC with robust in vitro and in vivo anti-tumor activity ◦ Published two articles in Nature Communications providing preclinical validation for the evaluation of UCART123 to treat AML and BPDCN ...
Cellectis (NASDAQ:CLLS) is scheduled to announce Q1 earnings results on Thursday, May 12th, after market close. The consensus EPS Estimate is -$0.66 and the consensus Revenue Estimate is $18.51M (-33.8% Y/Y). Over the last 2 years, CLLS has beaten EPS estimates 50% of the time and has be...
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report f...
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that Calyxt, Inc. (Nasdaq: CLXT), a plant-base...
Preclinical data demonstrates that UCART123 effectively eliminates AML with no major impact on normal hematopoietic progenitor cells Preclinical data shows proof-of-principle that UCART123 cells have potent anti-BPDCN activity Human evaluation of UCART123 is curr...
Cellectis is developing custom TALEN® for Cytovia to develop gene-edited iPSC-derived Natural Killer cells Cytovia and Isleworth Healthcare Acquisition Corp. announce business combination agreement and combined company is expected to be listed on NASDAQ under the ti...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...